Australia Cancer Immunotherapy Market Size & Outlook
- Pharmaceuticals
- Oncology Drugs
- Cancer Immunotherapy Market Outlook
- Oncology Drugs
Global Market
Related Markets
Ask a question about the cancer immunotherapy market
Australia cancer immunotherapy market highlights
- The Australia cancer immunotherapy market generated a revenue of USD 1,542.1 million in 2025 and is expected to reach USD 2,807.7 million by 2033.
- The Australia market is expected to grow at a CAGR of 7.8% from 2026 to 2033.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2025 | USD 1,542.1 million |
| Market revenue in 2033 | USD 2,807.7 million |
| Growth rate | 7.8% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Australia accounted for 1.0% of the global cancer immunotherapy market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 6,761.3 million by 2033.
Checkpoint inhibitors have heralded a new era for cancer treatment in Australia, with Opdivo and Keytruda at the forefront. Among all cancers, cancer immunotherapy was deemed most successful in the treatment of melanoma, which records the highest prevalence in Australia.
Monotherapy or combinatorial immunotherapy has been successfully applied in over 50% of melanoma patients and is likely to demonstrate similar results in lung & kidney cancer over the forecast period. Checkpoint inhibitors have also proved effective in the treatment of HNSCC, bladder cancer, and Hodgkin lymphoma.
Favorable reimbursement schemes in the country is an additional driving factor of the cancer immunotherapy market. A possible alternate strategy being discussed across medical reimbursement forums in Australia is the pay-for-performance scheme, wherein manufacturers are reimbursed only if the drug is successful in patients.
No credit card required*
Publish Date: Dec 03, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Immunocore Holdings PLC ADR | View profile | 497 | 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY | www.immunocore.com |
Australia Cancer Immunotherapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Immunotherapy Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 68.0% in 2025.
Horizon Databook has segmented the Australia cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.
Checkpoint inhibitors have heralded a new era for cancer treatment in Australia, with Opdivo and Keytruda at the forefront. Among all cancers, cancer immunotherapy was deemed most successful in the treatment of melanoma, which records the highest prevalence in Australia.
Monotherapy or combinatorial immunotherapy has been successfully applied in over 50% of melanoma patients and is likely to demonstrate similar results in lung & kidney cancer over the forecast period. Checkpoint inhibitors have also proved effective in the treatment of HNSCC, bladder cancer, and Hodgkin lymphoma.
Favorable reimbursement schemes in the country is an additional driving factor of the cancer immunotherapy market. A possible alternate strategy being discussed across medical reimbursement forums in Australia is the pay-for-performance scheme, wherein manufacturers are reimbursed only if the drug is successful in patients.
- Australia Cancer Immunotherapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal Antibodies
- Check Point Inhibitors
- Oncolytic Viral Therapies and Cancer Vaccines
- Australia Cancer Immunotherapy Market Application Outlook (Revenue, USD Million , 2021-2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Other Applications
- Australia Cancer Immunotherapy Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Australia Cancer Immunotherapy Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals and Clinics
- Cancer Research Centers
- Other End users
Reasons to subscribe to Cancer Immunotherapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cancer Immunotherapy Market Outlook databook
- Our clientele includes a mix of Cancer Immunotherapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Cancer Immunotherapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Cancer Immunotherapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Cancer Immunotherapy Market, 2021-2033 (US$M)
Australia cancer immunotherapy market statistics, by product, 2021-2033 (US$M)
